Trial Profile
A Phase IV, Single Arm, Open-Label Study to Determine the Efficacy and Safety of Ledipasvir/Sofosbuvir (LDV/SOF) in Treatment-Naive Alcoholic Subjects With Chronic Genotype 1 Hepatitis C Infection
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Jan 2024
Price :
$35
*
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 22 Feb 2023 Status changed from active, no longer recruiting to completed.
- 09 Dec 2019 Planned primary completion date changed from 1 Aug 2019 to 1 Aug 2020.
- 18 Oct 2018 Status changed from recruiting to active, no longer recruiting.